ABSTRACT:
This review article analyzes a matrix-based risk assessment methodology as it relates to defining how much effort or formality is required for a pharmaceutical company's cleaning validation activities. Cleaning validation has always been considered primarily as a compliance activity, but in current times, it is also seen as having a scientific basis and guidelines for consistency with regulatory criteria (ICH Q9, GMP, FDA, EMA, WHO). The research identifies and demonstrates the application of risk assessment tools (i.e., matrix models such as the Shirokizawa Matrix) that provide an integrated evaluation of key parameters related to the assessment of cleaning validation requirements (i.e., product toxicity [HBEL / PDE], processing capability [Cpu], design of equipment, and analytical sensitivity). The use of a matrix approach allows for the classification of risks as low, medium, or high, which ultimately assists with determining how much cleaning validation will be required for an activity. This article also discusses the various stages associated with lifecycle validation, the use of a worst-case scenario for the selection of a product being cleaned, and the application to multi-product facilities. Risk management tools, such as Failure Mode Effects Analysis and Hazard Analysis & Critical Control Point analysis, enhance decision making by aiding resource allocation and enabling regulatory compliance. New technology solutions including digital validation systems, artificial intelligence-based analytics, and real-time monitoring make it simpler to use scalable, data-driven validation methods.